243 related articles for article (PubMed ID: 32912036)
1. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Verlinden NJ; Walter C; Raina A; Benza RL
J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
3. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
4. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Jiménez A; Ais A; Beaudet A; Gil A
Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
[TBL] [Abstract][Full Text] [Related]
5. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
[TBL] [Abstract][Full Text] [Related]
6. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
7. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
8. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204
[TBL] [Abstract][Full Text] [Related]
9. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
10. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
11. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
[TBL] [Abstract][Full Text] [Related]
12. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
14. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
15. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
17. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
18. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
19. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
20. Inhaled iloprost as an add-on therapy for advanced pulmonary arterial hypertension: An Indian perspective.
Bobhate P; Gupta RK; Karande T; Kulkarni S
Natl Med J India; 2022; 35(6):338-343. PubMed ID: 37167510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]